FDA floats new rules for testing Alzheimer’s drugs.

For years now the gold standard for R&D in Alzheimer’s disease has focused on generating convincing evidence that any new therapy being studied could slow the cognitive decline of patients and help preserve their ability to perform the kind of daily functions that can keep a patient independent for a longer period of time.  Read more.

human brain.jpg

Author: Dr. Baek

- Scientist (Microbiology, Synthetic Biology, Molecular Biology). - Founder / CEO of the biotech company Peption LLC. - Passionate about biotechnological innovations to address important global health issues.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s